# A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

> **NCT05229068** · PHASE3 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSV MAT

## Key facts

- **NCT ID:** NCT05229068
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-11
- **Primary completion:** 2023-11-06
- **Final completion:** 2024-10-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in this study.
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05229068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05229068, "A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05229068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*